Automate Your Wheel Strategy on SRPT
With Tiblio's Option Bot, you can configure your own wheel strategy including SRPT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SRPT
- Rev/Share 25.3205
- Book/Share 13.8502
- PB 1.3235
- Debt/Equity 0.9974
- CurrentRatio 2.8882
- ROIC -0.0008
- MktCap 1791086622.0
- FreeCF/Share -4.5053
- PFCF -4.0564
- PE -30.9965
- Debt/Assets 0.3679
- DivYield 0
- ROE -0.0442
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | SRPT | JP Morgan | Underweight | Neutral | -- | $24 | July 29, 2025 |
| Initiation | SRPT | Bernstein | -- | Market Perform | -- | $13 | July 29, 2025 |
| Reiterated | SRPT | H.C. Wainwright | -- | Sell | -- | $5 | July 29, 2025 |
| Upgrade | SRPT | Oppenheimer | Perform | Outperform | -- | $37 | July 29, 2025 |
| Upgrade | SRPT | Barclays | Underweight | Equal Weight | -- | $22 | July 29, 2025 |
| Downgrade | SRPT | Barclays | Equal Weight | Underweight | -- | $10 | July 28, 2025 |
| Downgrade | SRPT | JP Morgan | Neutral | Underweight | -- | -- | July 25, 2025 |
| Initiation | SRPT | Citigroup | -- | Sell | -- | $7 | July 24, 2025 |
| Downgrade | SRPT | BofA Securities | Neutral | Underperform | -- | $10 | July 23, 2025 |
| Downgrade | SRPT | Barclays | Overweight | Equal Weight | -- | $18 | July 22, 2025 |
News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
SRPT LAWSUIT ALERT: The Gross Law Firm Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Aug. 11, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the federal securities laws. Shareholders who purchased the Company's securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.
Read More
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
Read More
SRPT COURT NOTICE: Sarepta Therapeutics Investors may have been Affected by Fraud -- Contact BFA Law before August 25 if You Suffered Losses (NASDAQ:SRPT)
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.
Read More
These Stocks Are Moving the Most Today: Coinbase, MicroStrategy, Sarepta, Nvidia, AMD, and More
Published: August 11, 2025 by: Barrons
Sentiment: Neutral
Coinbase and MicroStrategy stocks rose as Bitcoin price surged. Shares of Sarepta, Nvidia and AMD were falling in early trading Monday.
Read More
SRPT INVESTOR NOTICE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Published: August 08, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Aug. 8, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, all datesinclusive (the "Class Period"), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v.
Read More
SRPT Deadline: SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
Published: August 08, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 8, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the "Class Period"), of the important August 25, 2025 lead plaintiff deadline. So What: If you purchased Sarepta Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Published: August 08, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Sarepta between June 22, 2023 and June 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Aug. 8, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sarepta Therapeutics, Inc. ("Sarepta" or the …
Read More
Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
Published: August 06, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Sarepta Therapeutics (SRPT) Announces Restructuring and ELEVIDYS Black Box Warning, EMA Recommends Refusal of Marketing Authorization, Securities Class Action Pending – Hagens Berman
Published: August 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- On July 16, 2025, Sarepta Therapeutics (NASDAQ: SRPT) announced a major restructuring that involves, in part, a 36% workforce reduction (500 employees) and other steps to annually save about $400 million. The company also agreed with the FDA to include a black box warning of acute liver injury and acute liver failure in Sarepta's ELEVIDYS label.
Read More
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.
Read More
Sarepta Therapeutics (SRPT) Announces Restructuring and ELEVIDYS Black Box Warning, EMA Recommends Refusal of Marketing Authorization, Securities Class Action Pending – Hagens Berman
Published: August 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- On July 16, 2025, Sarepta Therapeutics (NASDAQ: SRPT) announced a major restructuring that involves, in part, a 36% workforce reduction (500 employees) and other steps to annually save about $400 million. The company also agreed with the FDA to include a black box warning of acute liver injury and acute liver failure in Sarepta's ELEVIDYS label. ELEVIDYS is the company's gene therapy drug intended to treat a limited category of people with Duchenne muscular dystrophy.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Sarepta Therapeutics (SRPT) Tanks 36% After 3rd Patient Death, SRPT Securities Class Action Pending – Hagens Berman
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, July 30, 2025 (GLOBE NEWSWIRE) -- On July 18, 2025, investors saw the price of their shares in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) collapse again – this time, shares closed down $7.89 (-36%) - after the company reported the death of a third patient who was being treated with one of its experimental gene therapy drugs.
Read More
SRPT INVESTORS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investors may have been Affected by Fraud – Contact BFA Law by August 25 about Potentially Recovering Losses
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.
Read More
Opinion | On Sarepta, a Welcome FDA Reversal
Published: July 29, 2025 by: WSJ
Sentiment: Positive
After our editorial, the agency relents to allow a Duchenne treatment.
Read More
Sarepta finally gets some good news: A patient death wasn't its DMD drug's fault.
Published: July 29, 2025 by: Market Watch
Sentiment: Positive
Sarepta Therapeutics' stock was soaring Tuesday after the FDA recommended lifting the pause on the company's Duchenne muscular dystrophy drug, but analysts worry it will take time for patients and doctors to feel safe using it.
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Published: July 29, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Sarepta between June 22, 2023 and June 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , July 29, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sarepta Therapeutics, Inc. ("Sarepta" …
Read More
Sarepta shares surge after FDA lifts pause on muscular dystrophy treatment
Published: July 29, 2025 by: Proactive Investors
Sentiment: Positive
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares jumped 25% at the open on Tuesday after the US Food and Drug Administration recommended the company lift a voluntary pause on shipments of its gene therapy ELEVIDYS for ambulatory Duchenne muscular dystrophy (DMD) patients. The regulator's move follows its determination that the death of an eight-year-old patient in Brazil, which had prompted a temporary halt, was unrelated to the therapy.
Read More
Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – SRPT
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
Read More
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT
Published: July 28, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 28, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the federal securities laws. Shareholders who purchased the Company's securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: July 28, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Published: July 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options
Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Published: July 23, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Sarepta between June 22, 2023 and June 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , July 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sarepta Therapeutics, Inc. ("Sarepta" …
Read More
Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – SRPT
Published: July 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
Read More
How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Negative
Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price due to concerns over milestone payments and clinical program continuity. Arrowhead's financial position remains strong, even with a reduced runway caused by the lack of promised milestone payments from Sarepta. In today's article, I discuss a range of potential outcomes for the collaboration between Sarepta Therapeutics and Arrowhead Pharmaceuticals and what Arrowhead can do with its pipeline and financials.
Read More
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Negative
Sarepta stock down as it halts U.S. Elevidys shipments after FDA pressure and safety concerns tied to patient deaths due to liver failure.
Read More
About Sarepta Therapeutics, Inc. (SRPT)
- IPO Date 1997-06-04
- Website https://www.sarepta.com
- Industry Biotechnology
- CEO Douglas S. Ingram
- Employees 1372